TYHT SHINECO INC

Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

Shineco Subsidiary Registered as a Member of Pharmaceutical Chamber of Commerce

Association with the Chamber Will Improve Visibility

and Could Lead to Potential Collaborations

BEIJING, June 08, 2023 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that in May 2023, its wholly owned subsidiary. Shineco Life Science Research Co., Ltd., was registered as a member of the All-China Federation of Industry and Commerce Medical & Pharmaceutical Chamber of Commerce (the “Pharmaceutical Chamber of Commerce”), and Ms. Jennifer Zhan, CEO of Shineco, became a member of the Pharmaceutical Chamber of Commerce.

The Pharmaceutical Chamber of Commerce is a national level association that operates directly under the All-China Federation of Industry and Commerce and is registered with China’s Ministry of Civil Affairs. The Pharmaceutical Chamber of Commerce consists of a wide array of pharmaceutical enterprises throughout China, and it serves as an important link to the government, supports the interests of its members and serves as a platform for promoting the industry’s development.

Ms. Jennifer Zhan, CEO of Shineco, commented, “We are pleased that Shineco Life Science Research has been registered with the All-China Federation of Industry and Commerce Medical & Pharmaceutical Industry Chamber of Commerce. I am also very honored to have been named a director of the Pharmaceutical Chamber of Commerce for this essential industry whose products and discoveries help to care for the health and well-being of people’s lives.”

“We believe that our Company will benefit from being a member of the Pharmaceutical Chamber of Commerce as it will enable us to access industry resources, network with other businesses and professionals in the industry, increase our visibility in our product areas, and enhance our credibility as well as our commercial activities. We look forward to taking an active and productive role to promote our business and the pharmaceutical industry as a whole.”

There are approximately 1,500 direct members and more than 50 group members of the Chamber of Commerce that encompass the entire pharmaceutical industry of more than 5,000 pharmaceutical companies, covering all provinces and municipalities across China, with eight committees that organize and focus its activities.

About Shineco, Inc.

Shineco, Inc. (“Shineco” or the “Company) aims to ’care for a healthy life and improve the quality of life’ by providing safe, efficient, and high-quality health products and services to society. Shineco has researched and developed 33 vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious food. For more information about Shineco, please visit .

Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may”, “will”, “should”, “could”, “intend”, “expect”, “plan”, “budget”, “forecast”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “continue”, “evaluating” or similar words. Forward-looking statements should not be relied upon because they are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Examples of forward-looking statements include, among others, statements we make regarding the innovativeness and market position of our products and services, our competitive strengths. You are cautioned not to rely on any forward-looking statements. Actual results may differ materially from historical results or those indicated by the forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with the Company’s ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the ability to obtain all necessary regulatory approvals in the jurisdictions where it intends to market and sell its products the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulations, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and speak only as of the date of this press release, and Shineco assumes no obligation to update any forward-looking statements except as required by the applicable rules and regulations.

For more information, please contact:

Shineco,Inc.



Mobile: 0

Precept Investor Relations LLC

David J. Rudnick



Mobile:



EN
08/06/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SHINECO INC

 PRESS RELEASE

Shineco, Inc. to Effect 50:1 Reverse Stock Split

Shineco, Inc. to Effect 50:1 Reverse Stock Split Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price BEIJING, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (Nasdaq:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical devices, today announced that the Company's Board of Directors has approved a 50:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on August 11, 2025. The Company's Common Sto...

 PRESS RELEASE

Management Confidence: Shineco Executives Launch up to $2M Open-Market...

Management Confidence: Shineco Executives Launch up to $2M Open-Market Stock Purchase Program BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that Ms. Jennifer Zhan, the Company’s chief executive officer, and Mr. Sam Wang, the Company’s chief financial officer, will jointly initiate a stock purchase program (the “Stock Purchase Program”) to purchase up to $2,000,000 of the Company’s common stock, par value $0.001 per share (the “Common Stoc...

 PRESS RELEASE

Shineco’s Subsidiary InfiniClone Partners with Total World Marketing f...

Shineco’s Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited ("InfiniClone"), Shineco's majority-owned subsidiary in which the Company acquired a 51% equity interest on April 25, 2025, has officially launched its Southeast Asian market expansion strategy as it has reached a strategic distribution agreement wit...

 PRESS RELEASE

Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Comp...

Shineco Announces Acquisition of Singapore Evolutionary Stem Cell Company Expanding the Frontiers of Regenerative Medicine BEIJING, April 23, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on April 22, 2025, its subsidiary, Shineco Life Sciences Group Hong Kong Limited ("Shineco Life Sciences"), entered into a Share Purchase Agreement (the "SPA") with Dr. Lim Kah Meng (the "Seller") to acquire 51% of the equity interest in InfiniClone Limited, a compa...

 PRESS RELEASE

Shineco Announces Acquisition of Medical Device Company

Shineco Announces Acquisition of Medical Device Company The Acquisition is Expected to Create Immediate Synergies with the Company’s Existing Medical Device Business  BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of the Company, entered into a Stock Purchase Agreement (“SPA”) with Yi Yang (the “Seller”), for 75% of an equity ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch